SANTA MONICA, Calif., June 22 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), one of the largest umbilical cord blood stem cell preservation companies (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, which earlier this month announced sales operation expansion into the European Union, said today it has signed an agreement with a marketing affiliate for expansion of its services into Panama, Bermuda and Aruba. The marketing arrangement is expected to target hospitals and obstetricians/gynecologists in those areas. Cord Blood will receive revenue from the sale of cord blood processing and storage services sold to each family. Marketing of such services will commence immediately.
"We are excited to begin marketing our cord blood processing and storage services in areas where we have the first-mover advantage," said founder and CEO Matthew Schissler. "We will be the first party offering such services in Bermuda and Aruba, and the second party in Panama. Based upon the experience in North America, we believe that being first in the market will provide us with compelling advantages. We see the storage of stem cells internationally as potentially very profitable. While the size of these overall countries is relatively small, given the highly attractive demographics of their population we believe the opportunities could be lucrative. The advantages of storing stem cells at birth, and at other times in life, are becoming well known worldwide."
Panama, with a population of 3.3 million, has become an international business center in Central America, with a fast growing economy and the highest per capita consumer spending in the region. Aruba, an affluent island in the southern Caribbean, is overseen by the Netherlands, while Bermuda, a British territory in the North Atlantic, has previously had the world's highest GDP per capita.
SANTA MONICA, Calif., June 11 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), one of the largest umbilical cord blood stem cell preservation companies (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today it has begun due diligence for sales operation expansion into the European Union, specifically Belgium and Italy.
Cord Blood America's international partner, a.bourkas Co., United, has had operations in Greece since 2006 and has established a sales operation in Germany.
"This is potentially a very profitable new frontier in the stem cell industry and we are pleased to be one of the leaders in this expansion and growth," said founder and CEO Matthew Schissler. "We started small in Europe, and believe now, for a number of fiscal reasons, would be a good time to look at expansion. The value of storing umbilical cord blood stem cells at birth is becoming well known worldwide."
SANTA MONICA, Calif., May 27 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it has reduced its secured debt by a total of $4.194 million in the first five months of 2009.
"On April 6th, 2009, Cord Blood America announced it had decreased its debt by $1.75 million this year," said Matthew Schissler, Cord Blood America Founder and CEO. "Since that time, we have further reduced our secured debt by $1.627 million and have eliminated liquidated damages totaling $817,000."
"We have been very forthright with our investors. We have said there are three strong pillars needed to take CBAI to the next level. One is debt reduction, and today's announcement shows our achievement in that sector. The second is organic growth, and our deferred revenues for the first quarter were up 20 percent. The third pillar is acquisitions, and we recently announced Cord Blood America is in the process of building or buying a stem cell laboratory for increased acquisition capacity and higher gross margin," Mr. Schissler said.
SANTA MONICA, Calif., May 15 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that Company founder and CEO Matthew Schissler, in a FirstCall In audio interview with analyst Francis Gaskins, explains the thought process behind the Company owning its own stem cell laboratory.
The interview and associated web links are available at http://www.investorcalendar.com/IC/ClientPage.asp?ID=145109.
An analyst report compiled by Mr. Gaskins, which details Cord Blood America's effort to become cash flow positive this year, is available at http://gaskinsco.com/linkto-cbai.shtml.
